# Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART

> **NCT03706950** · — · UNKNOWN · sponsor: **Viriom** · enrollment: 2000 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Elpida® + 2 NRTIs

## Key facts

- **NCT ID:** NCT03706950
- **Lead sponsor:** Viriom
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706950, "Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03706950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*